Latest research on Fluticasone

Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma. Fluticasone proprionate is marketed under several different brand names such as Flonase®. Fluticasone propionate is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patients over 12 years old for symptomatic relief of seasonal allergic rhinitis.

Fluticasone interactions

Ultimately, a combination of topical Fluticasone, Cyclosporine, Acitretin, oral Prednisone, and intramuscular methotrexate yielded mild to moderate improvement for periods of time. [source, 2016]
The administration of topical Fluticasone, Cyclosporine, and oral methotrexate were continued, under the presumed diagnosis of atopic dermatitis. [source, 2016]
The annual incidence of moderate or severe exacerbations, systemic corticosteroid prescriptions, and hospitalizations were reduced significantly in the TORCH study with both the β2-agonist Salmeterol and corticosteroid Fluticasone. [source, 2016]
The overall risks of pneumonia were found to be significantly related to Fluticasone but not Budesonide [2122]; however, in a recent Cochrane group meta-analysis, no significant difference was found with respect to serious adverse events or mortality between Fluticasone and Budesonide among COPD patients [23]. [source, 2016]
Also in a retrospective pooled analysis of 5 RCTs comparing Zafirlukast to Fluticasone as monotherapy, the effects of Zafirlukast appeared to be lost in older adults (aged ≥50 years) [72]. [source, 2016]
Compared with placebo, ICS such as Fluticasone propionate (FP) and Budesonide reduce exacerbations by up to 20% as monotherapy, and up to 30% in combination with a long-acting β2-agonist (LABA). [source, 2016]
Fourteen studies evaluated ICS therapy (beclomethasone, Budesonide, Fluticasone) [22–35]. [source, 2016]
The other seven studies evaluated the efficacy of ICS therapies (beclomethasone, [23, 30, 33] Fluticasone, [26, 27] and Budesonide [22, 28]) compared against inhaled placebo. [source, 2016]
In regard to lower (<1000 μg/day) doses, one study (Budesonide [22]) reported improved outcomes at a dose of 800 μg/day, whereas two studies (beclomethasone [34] & Fluticasone [26]) report no benefit of ICS therapy with doses of 17 to 250 μg [26, 34]. [source, 2016]
Inhalation regimens in the trial were as follows: Spiriva 18 (100% of the patients), Seretide Diskus 50/500 and 50/250 (54% and 4%), Symbicort 9/320 and 4.5/160 (18% and 7%), Inuvair 12/200 and 6/100 (11% and 4%), Pulmicort 400 and 200, Oxis 9, Onbrez 150, and Seretide MDI 25/250 (all 4%). [source, 2016]